Mon, 01 Jun 2015 11:00:00 GMT ~ Ignyta Announces Phase 1 Clinical Trial Data for Entrectinib
[Business Wire] - Ignyta, Inc. , a precision oncology biotechnology company, today announced that interim results from the company’s two Phase 1 clinical trials of entrectinib were presented in poster presentations, including a poster discussion, at the 2015 Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois.
Link: http://www.otcmarkets.com/stock/RXDX/company-info Ticker: $RXDX OTC Market Place: Not Available CIK code: 0001557421 Company name: Ignyta, Inc. Company website: http://www.ignyta.com Incorporated In: NV, USA
Business Description: Ignyta, Inc. is catalyzing personalized medicine with \"Rx/Dx\" solutions for cancer.Our goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. We achieve this goal by leveraging our proprietary cancer genomic and epigenomic knowledge bases to discover novel targets and deliver the next generation of targeted therapeutics accompanied by highly informative biomarkers for patient selection, treatment, and monitoring.Less >>
$RXDX share structure
## source: otcmarkets.com
Market Value: $376,404,143 a/o Jun 01, 2015 Shares Outstanding: 25,262,023 a/o Apr 30, 2015 Float: 7,336 a/o Dec 19, 2013 Authorized Shares: 100,000,000 a/o Dec 19, 2013 Par Value: Not Available
$RXDX extra dd links
Company name: Ignyta, Inc. Company website: http://www.ignyta.com